Articles tagged with Clinical Trials
Researchers have developed a technology called FarrSight-Twin that creates digital twins of real cancer patients to predict treatment response. The approach was tested on published clinical trials and showed accurate predictions in all simulated studies, with 75% response rate among patients receiving the predicted best treatment.
TYRA-300 shows promise in treating metastatic bladder cancer patients with FGFR3 gene mutations, achieving a 50% overall response rate and 100% disease control rate. The treatment also displays improved tolerability with lower side effects compared to existing pan-FGFR inhibitors.
A cohort study of children with vesicoureteral reflux found that glomerular filtration rate changes after urinary tract infections. The study used data from the Children With Vesicoureteral Reflux trial to assess estimated glomerular filtration rate changes in participants with vs without recurrent UTIs.
The myeloMATCH program offers a portfolio of biomarker-driven treatment trials to accelerate precision medicine in myeloid malignancies. Patients can enroll in clinical trials throughout their cancer treatment journey, with test results returned quickly to assign them to the most appropriate trial.
A new study suggests that MRI can predict patient outcomes and the risk of tumor reccurrence or spread for patients with rectal cancer who have undergone chemotherapy and radiation. This information could help doctors determine the best course of treatment, including whether to spare patients from invasive surgery.
Women who started an aerobic exercise program during chemotherapy reported improved cognitive function and quality of life compared to those receiving standard care. The study found that while cognitive performance was similar after chemotherapy completion, the exercise program had a positive impact on self-reported cognitive function.
A Phase I human clinical trial is commencing to test the efficacy and safety of transplantation of olfactory cell nerve bridges to treat chronic spinal cord injury. The trial combines olfactory ensheathing cells with long-term intensive rehabilitation.
This article provides practical recommendations for improving ethical oversight of clinical trials in the US. Key findings include enhanced regulatory mechanisms and training programs to ensure compliance with existing regulations.
A randomized clinical trial found that montelukast did not shorten the duration of COVID-19 symptoms among outpatients with mild to moderate illness. The study's findings suggest that montelukast is unlikely to be beneficial for treating mild to moderate COVID-19.
A €1.3 million consortium aims to rapidly deploy technology and develop new knowledge to end the Mpox outbreak in DRC and surrounding countries. The project will expand a trial exploring Mpox vaccination effectiveness in additional African countries.
A recent study published in eClinicalMedicine found that a combination of amubarvimab and romlusevimab did not reduce the occurrence of long COVID symptoms. The researchers assessed symptom diaries and health-related quality of life questionnaires, but saw no significant difference between treatment and placebo groups.
The two-year progression-free survival rate was 92% on the N-AVD arm compared to 83% on the BV-AVD arm, with fewer side effects and lower mortality rates. The study's results support the use of nivolumab-AVD as a standard treatment for stage 3-4 classic Hodgkin lymphoma.
A new clinical trial has found that the mpox vaccine is safe and generates an immune response equivalent to adults, providing hope for adolescents affected by the virus. The study's interim results were presented at IDWeek2024 conference in Los Angeles.
A randomised clinical trial shows that integrating physiotherapy and cognitive-behavioural therapy is effective in improving symptoms and physical aspects of the quality of life of patients with functional movement disorders. The study suggests this approach could be cost-effective and opens up new lines of research.
A nationwide clinical trial found that electronic letter-based nudges significantly increased influenza vaccination in young and middle-aged patients with chronic diseases. The results suggest a scalable, cost-efficient strategy to boost public health.
Researchers propose utilizing human 3D skin models to assess drug binding properties across different skin types. Genetic variations among minority groups can lead to starkly different drug responses across races and ethnicities.
The first phase of the Ceramide Ring Trial has been published in Nature Communications, representing a significant landmark in lipidomics. The trial established ceramide reference values, which are essential for understanding the roles of lipids in health and disease.
The study marked a significant milestone in lipidomics, establishing reference values for ceramides and plasma lipids involved in cardiovascular disease risk prediction. The global network of laboratories achieved better-than-anticipated comparability in results using different methods and instrumentations.
A study found that screening frequency and breathing trial techniques did not affect the time to successful extubation. However, a combination of more frequent screening and pressure-supported SBTs increased the time to first successful extubation.
Researchers at Mass General Brigham discovered that combining two therapeutic agents can selectively kill tumor cells in triple negative breast cancer, differentiating them and triggering a process similar to involution. The study provides support for clinical trials testing this new approach.
Industry-sponsored trials have grown while federally funded enrollment remains flat, jeopardizing research in cancer prevention, screening, and health disparities. Diversified funding and strong advocacy are needed to ensure all patient populations benefit from research advancements.
Researchers found that patients had the same success rate when treated for 24 hours compared to 72 hours, with no difference in need for transfusion, ventilation, or vasopressors. This suggests that shorter octreotide therapy may be sufficient and could help reduce hospital stays and costs.
A crossover randomized clinical trial found that using lap or side positions for blood pressure readings leads to substantial overestimation. This misdiagnosis could have serious consequences, particularly for patients with hypertension.
Recent clinical trials of neoadjuvant therapy before radical prostatectomy, such as the ACDC-RP trial, have struggled to show significant survival benefits. Researchers recommend maximal androgen blockade with an androgen receptor pathway inhibitor as the 'backbone' of neoadjuvant therapy trials.
A study found that doxycycline post-exposure prophylaxis (doxy-PEP) did not significantly alter the overall composition of gut bacteria in individuals who took it for six months. However, the researchers noted signs of resistance building against tetracycline, a class of antibiotics to which doxycycline belongs.
A new non-invasive imaging technique has been shown to accurately detect clear-cell renal cell carcinoma, the most common form of kidney cancer. The technique uses a monoclonal antibody drug that targets the protein CA9, highly expressed in up to 95% of clear cell kidney cancers.
A study suggests that online insomnia treatment, SHUTi, can provide meaningful relief for caregivers struggling with sleep difficulties. The program showed promising results in improving sleep quality and reducing stress among high-intensity caregivers, those shouldering the greatest responsibilities in caring for their loved ones.
A randomized phase 3 trial found that extended lymph node removal in bladder cancer surgery does not improve disease-free or overall survival but increases the risk of complications and death. The standard bilateral pelvic lymphadenectomy is considered a sufficient approach for these patients.
Pragmatic clinical trials compare treatments in everyday clinical settings, but adoption of trial findings has been inconsistent. To address this, the authors propose adaptive trial designs to align trial goals with healthcare system needs. By doing so, they aim to generate evidence that truly improves patient care.
A randomized trial halted after patients in the control arm reached a record high two-year progression-free survival rate of 98%. Deintensified treatments involving lower radiation dose and immunotherapy did not perform as well as standard chemoradiation.
A multi-center phase III trial found photon- and proton-based radiation therapies to be similarly safe and effective in treating low- and intermediate-risk prostate cancer. Patients treated with either IMRT or proton therapy reported no significant differences in quality of life, tumor control, or progression-free survival.
A survey found that spiritual beliefs and distrust of clinical research contribute to Black patients' hesitation to enroll in cancer trials. Despite trusting their medical teams, some patients express concerns about the purpose of research and its potential impact on their health and community.
A new study found that the IOTA ADNEX ultrasound model can detect up to 96% of ovarian cancers in postmenopausal women, outperforming the current standard test. The research team recommends replacing the risk of malignancy (RMI1) test with the IOTA ADNEX model.
A new study found that hypofractionation does not increase complications for patients with breast cancer who undergo mastectomy and plan breast reconstruction. The trial enrolled 898 patients and showed that reducing treatment time by nearly half is safe and effective, saving patients time and money.
A recent study found that limiting food consumption within a 10-hour window per day improved key indicators of heart health in adults with metabolic syndrome. The study demonstrated significant reductions in blood sugar and cholesterol levels, as well as lower levels of hemoglobin A1c, a marker of long-term blood sugar management.
A new trial suggests that adding immunotherapy to chemoradiation can extend survival in patients with limited-stage small cell lung cancer. However, the findings also indicate that delivering the treatments at different times yields varying results, with concurrent treatment not offering improved survival benefits.
A clinical trial found time-restricted eating improved blood sugar regulation and reduced markers of metabolic dysfunction in adults with metabolic syndrome. Participants who followed a customized eight-to-ten-hour eating window saw significant improvements compared to standard treatments.
A pooled analysis of three large, phase III clinical trials found that more than 40% of brain metastases patients can fully reverse cognitive losses with conformal radiation techniques. Recovery was more likely for those treated with highly targeted radiation compared to standard whole-brain treatment.
A phase II clinical trial found that radiopharmaceuticals, specifically 177Lu-Dotatate, can extend progression-free survival for patients with refractory meningioma by nearly 80% after six months. The therapy offers a safe and effective treatment option for those with aggressive tumor growth.
Leading researchers from Penn Medicine will showcase clinical trial results and new data on FLASH radiation therapy. The institution is one of the world’s leading academic medical centers, with a proud history of groundbreaking discoveries and innovations.
Long-term treatment with the nonsteroidal mineralocorticoid receptor antagonist finerenone is estimated to extend event-free survival by up to 3 years among people with heart failure. The FINEARTS-HF randomized clinical trial found this benefit in patients with mildly reduced or preserved ejection fraction.
A recent study reveals that pharmaceutical industry sponsors dominate US cancer research, with a substantial increase in industry-sponsored clinical trials over the past decade. Federally funded studies have been underinvested and have missed opportunities for scientific advancements.
Recent randomized trials confirm the benefit of endovascular therapy over medical management in reducing disability in selected patients. Patient selection criteria based on clinical and imaging criteria can be used to determine eligibility for endovascular therapy up to 24 hours after symptom onset.
A single-dose gene therapy has been shown to significantly reduce bleeding episodes in adults with hemophilia B, with an average reduction of 71% compared to standard treatment. The therapy, which enables the liver to produce clotting factor IX, has been FDA-approved for use in patients with this genetic disorder.
A study suggests that semaglutide may have therapeutic value in preventing opioid overdoses by reducing the associated risk. The results require further validation, but the findings indicate a potential benefit for patients with comorbid type 2 diabetes and opioid use disorder.
A randomized clinical trial found home-based phototherapy to be as effective as office-based treatment for plaque and guttate psoriasis, while reducing patient burden. The study suggests that this approach could become a viable option for everyday clinical practice.
Researchers at St. Jude Children's Research Hospital found that patients with ETV6::RUNX1 and high-hyperdiploid B-ALL can achieve positive outcomes with low-intensity chemotherapy, tailoring treatment based on genetic subtypes and early treatment response. This approach reduces side effects and improves event-free survival rates.
The #HOPE4LIVER trial demonstrated the safety and efficacy of histotripsy as a treatment for primary and metastatic liver tumors, achieving a 95% technical success rate. The procedure's non-invasive nature and ability to spare critical vessels and bile ducts offer promising alternatives to traditional treatments.
A randomized clinical trial found that a voice-activated cognitive behavioral therapy program improved insomnia symptoms in breast cancer survivors. The intervention, delivered in an in-home setting, demonstrated efficacy in reducing sleep disturbances and enhancing overall quality of life.
The SWOG S1712 trial found that adding ruxolitinib to standard tyrosine kinase inhibitor (TKI) treatment significantly increased the percentage of patients with deep molecular responses, warranting treatment discontinuation. This combination may lead to improved health-related quality of life and reduced healthcare costs.
A new risk prediction model identifies patients with advanced cancer who are at highest risk for unplanned emergency room visits and hospital stays. The model, developed by researchers from the SWOG Cancer Research Network, considers factors such as performance status, comorbidities, and cancer type.
A nonrandomized clinical trial found that wearable devices can increase moderate-to-vigorous physical activity and reduce dyspnea at 6 months post-lung cancer surgery. This suggests a promising role for wearable devices in personalizing perioperative rehabilitation strategies.
A phase 1b/2 clinical trial found a combination of immunotherapy and FGFR inhibitor to be safe and tolerable in patients with locally advanced or metastatic bladder cancer. The treatment showed increased response rates, including 54% for patients with high FGFR mRNA expression.
A new prostate biopsy technique, transperineal biopsy, has been shown to lower the risk of infection compared to traditional biopsies. The PREVENT trial found no infections among men who underwent the transperineal procedure, while those with traditional transrectal biopsies had a 1.6% infection rate despite receiving antibiotics.
Researchers discovered ponsegromab, a monoclonal antibody, improves symptoms of cachexia by blocking the GDF-15 hormone. The treatment shows minimal side effects and boosts weight gain and patient activity in cancer patients.
The Cancer Cooperative Group System is being re-engineered to bring new money to correlative science research through public-private partnerships, aiming to remove barriers for researchers to access biological samples. This will facilitate the integration of innovative science into cancer clinical trials.
A recent clinical trial found that an IV iron treatment called ferric carboxymaltose works faster and better than oral iron tablets in treating anaemia during pregnancy. The study showed improved haemoglobin levels and iron correction with the IV treatment, with comparable side effects.
Researchers found pomalidomide to be safe and effective in reducing nosebleed severity, improving quality of life, and decreasing the need for blood transfusions in adults with hereditary hemorrhagic telangiectasia. The trial stopped early due to successful findings, offering a promising treatment option for this rare bleeding disorder.
A clinical trial found that an oral cancer drug reduced nosebleed severity and improved quality of life in patients with hereditary hemorrhagic telangiectasia (HHT). The PATH-HHT study showed significant improvements in disease manifestations, including severe nosebleeds and chronic gastrointestinal bleeding.
A randomized clinical trial shows that transitioning insomnia care away from long-term sedatives to cognitive behavioral therapy can be achieved through a mailed, direct-to-patient approach. This method reduces sedative use and improves sleep outcomes in older adults.